Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

516
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
516
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

295
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
295
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

358
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
358
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

430
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
430
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

647
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
647
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

433
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
433

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026
Same author

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026
Same author

Cardiorenal Syndrome and Depressive Symptoms: Exploring the Mood-Kidney Link With Heart Failure Risk in a Post-hoc Analysis of SPRINT.

Kidney medicine·2026
Same author

A comprehensive review on chemical structure, quality control, pharmacological effects, and structure-activity relationship of saponins from Zhuzishen ().

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·2026
Same author

Clinical Characteristics and Long-Term Outcomes of Patients With Fibrosing Mediastinitis: A Multicenter Retrospective Cohort Study.

JACC. Asia·2026
Same author

Kidney Disease: Improving Global Outcomes (KDIGO) life cycle of guideline development series: part 2: from initiation to publication: the KDIGO guideline development process.

Kidney international·2026

関連する実験動画

Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K

臨床症状

Amara Sarwal1, Ravinder Singh1, Guo Wei1

  • 1University of Utah, Salt Lake City, UT, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
まとめ
この要約は機械生成です。

2型糖尿病患者におけるリラグルチドの使用は、セマグルチドと比較してアルツハイマー病および認知症のリスク低下と関連していた。リラグルチドは、他のグルカゴン様ペプチド-1受容体作動薬と比較して死亡リスクの低下も示した。

キーワード:
2型糖尿病GLP-1受容体作動薬リラグルチドセマグルチドデュラグルチド認知症アルツハイマー病死亡リスク

さらに関連する動画

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

関連する実験動画

Last Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

科学分野:

  • 内分泌学、神経科学、薬理学

背景:

  • リラグルチド、セマグルチド、デュラグルチドなどのグルカゴン様ペプチド-1受容体作動薬（GLP-1RA）は、2型糖尿病（T2D）管理における鍵となる。GLP-1RAの使用が認知症リスクを低下させる可能性を示唆するエビデンスが出現しているが、クラス内での違いを調査する必要がある。

研究 の 目的:

  • リラグルチド、セマグルチド、またはデュラグルチドを開始したT2D患者におけるアルツハイマー病および関連認知症（AD/ADRD）のリスクを比較すること。これらのGLP-1RAと死亡リスクとの関連を評価すること。

主な方法:

  • アクティブコントローラー新規使用者デザイン研究には、リラグルチド、セマグルチド、またはデュラグルチドを開始した21,173人のT2D退役軍人が含まれた。一般化傾向スコア逆確率重み付け（IPW）により交絡因子を制御した。IPW Coxモデルを用いて、AD/ADRD、死亡、および複合アウトカムのリスクを評価した。

主要な成果:

  • リラグルチドはセマグルチドと比較してAD/ADRDのリスクが低く（HR 0.68）、デュラグルチドと同程度のリスクを示した。セマグルチドはデュラグルチドと比較してAD/ADRDのリスクが高かった（HR 1.32）。リラグルチドは、全死因死亡およびAD/ADRD/死亡の複合アウトカムの最も低いリスクと関連していた。

結論:

  • リラグルチドは、セマグルチドと比較してAD/ADRDのリスクを低下させ、研究された他のGLP-1RAよりも死亡リスクを低下させた。デュラグルチドはリラグルチドと同様のAD/ADRDリスクを示したが、有意な死亡率の低下はなかった。